<DOC>
	<DOCNO>NCT00940121</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics three dos oral mirabegron formulation three different release rate versus three dos mirabegron administer intravenously ; study safety side effect oral IV dose mirabegron .</brief_summary>
	<brief_title>Pharmacokinetics Oral Mirabegron With Different Release Rates Versus Intravenous ( IV ) Mirabegron</brief_title>
	<detailed_description>Subjects randomly assign one three oral mirabegron dos randomly assign one three oral mirabegron dos randomly assign one six treatment sequence . For subject first treatment reference IV dose . Treatments 2 , 3 , 4 random order slow , fast target release oral dos mirabegron . Treatment 5 target release dose mirabegron different batch . There least 10 day washout dose administration .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>The subject must weigh least 45 kg body mass index ( BMI ) 20.0 32.0 kg/m2 The subject must normal clinically nonsignificant 12 lead ECG well normal clinically nonsignificant laboratory test result Female subject must postmenopausal ( define least 2 year without menses ) surgically sterile , practice effective contraception , continue use effective contraception study period . All female must nonlactating , negative pregnancy test result The subject must negative test result drug abuse alcohol screen The subject must good venous access arm The subject evidence QTc interval &gt; 430 msec male , &gt; 450 msec female The subject liver function test value ( ALT , AST , bilirubin ) upper limit normal The subject history presence psychiatric illness , serious active recurrent infection The subject previous history cancer basal cell carcinoma Stage 1 squamous cell carcinoma remission least 5 year The subject donate lose â‰¥ 450 mL blood within 56 day prior study drug administration donate plasma within 7 day prior study drug administration The subject receive anticipated receive prescription drug within 14 day ( within 30 day long act treatment depot formulation ) . Subject take overthecounter ( OTC ) medication , include complementary alternative medicine ( except oral contraceptive occasional use acetaminophen 2000 mg/day 4 day per week ) within 14 day The subject consume alcohol , xanthine derivativecontaining beverages/food ( tea/chocolate ) , grapefruit juice , grapefruitcontaining product Seville orange ( e.g. , bitter marmalade ) within 48 hour admission unit The subject use tobaccocontaining product nicotinecontaining product within 6 month The subject consume 5 unit alcoholic beverage ( one unit 12 ounce beer , 4 ounce wine 1 ounce spirit ) per week , history substance abuse , drug addiction , alcoholism within past 2 year The subject know hepatitis HIV1 and/or HIV2 , positive hepatitis A antibody IgM , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Healthy volunteer subject</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>YM178</keyword>
	<keyword>mirabegron</keyword>
	<keyword>IV infusion</keyword>
	<keyword>oral administration</keyword>
</DOC>